论文部分内容阅读
1972年美国NCI(国立癌症研究所)召开癌症BCG免疫疗法国际会议。会上讨论了在动物实验肿瘤系模型的抗癌免疫疗法以及BCG治疗人黑色素瘤和白血病的研究工作。NCI的动物实验模型是豚鼠种系2同系移植肝癌第10株,据报告BCG对同系肿瘤具有明显的抑制和使之退化的作用。当时BCG使人黑色素瘤缩小的效果令与会者大为震惊。自此,抗癌免疫盛行一时,几乎凡与机体防御机制有关的疗法都在抗癌免疫的名义下活跃起来。1976、1980年在美国Bethesda召开第二次和第三次抗癌免疫疗法会议,讨论人癌免疫的研究工作。第一次学会以来在抗癌免疫疗效的判定上缺乏确切的免疫学指标。1980年确定实行统计学上的“严密的随机分组观察”,并统一以生存日数的明显延长为考核
In 1972, the NCI (National Cancer Institute) held the International Conference on Cancer BCG Immunotherapy. At the meeting, the study of anti-cancer immunotherapy in animal experimental tumor lineage models and BCG treatment of human melanoma and leukemia was discussed. The animal experimental model of NCI is the 10th strain of guinea pig germline 2 homograft liver cancer, and it is reported that BCG has significant inhibition and degradation of syngeneic tumors. At that time, the effect of BCG on the shrinkage of human melanoma surprised the participants. Since then, anti-cancer immunity has prevailed. Almost all the mechanisms related to the defense mechanisms of the body have become active in the name of anti-cancer immunity. The Second and Third Anticancer Immunotherapy Conferences were held in Bethesda, USA, in 1976 and 1980 to discuss research on human cancer immunity. Since the first time of learning, there has been a lack of exact immunological indicators in the determination of the efficacy of anti-cancer immunity. In 1980, it was determined to implement statistical “rigorous randomized observations,” and unified assessments were based on the apparent extension of the number of survival days.